The grades of four Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

This week, Repros Therapeutics (NASDAQ:RPRX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.

This is a strong week for Johnson & Johnson (NYSE:JNJ). The company’s rating climbs to A from the previous week’s B. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. At present, the stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.

Bristol-Myers Squibb (NYSE:BMY) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. The stock price has risen 8% over the past month, better than the 2.9% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BMY stock.

Watson Pharmaceuticals (NYSE:WPI) is seeing ratings go up from a B last week to an A this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.